LH — Labcorp Holdings Inc. stock price, charts and financials

QT60Labcorp Holdings Inc.

Labcorp Holdings Inc. (NYSE: LH) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
312.34
+4.92+1.60%
OverviewShort InterestFilings
LHQT60Labcorp Holdings Inc.·NYSE
312.34+1.60%
News
Up 1.6% — OPKO Health: Mazdutide And MDX-2201 Could Change Everything (SeekingAlpha).
Medium confidence
TA
Loading chart...
Screen all →
DGX+0.76%$233.72WAT+5.69%$396.08MTD-0.55%$1437.00ILMN+2.45%$203.01GH+0.60%$159.79IQV-2.21%$228.20A-0.43%$139.20NTRA+1.79%$275.19
Snapshot
IndexS&P 500P/E25.83EPS (ttm)12.09Insider Own0.52%Shs Outstand82.00MPerf Week-0.60%
Market Cap25.61BForward P/E15.79EPS next Y19.78Insider Trans-6.22%Shs Float81.67MPerf Month9.83%
Enterprise Value32.05BPEG3.18EPS next Q4.60Inst Own-Short Float3.33%Perf Quarter23.45%
Income1.00BP/S1.78EPS this Y51.02%Inst Trans-Short Ratio4.15Perf Half Y15.56%
Sales14.35BP/B2.97EPS next Y8.34%ROA5.41%Short Interest2.72MPerf YTD24.50%
Book/sh105.16P/C180.37EPS next 5Y8.11%ROE11.57%52W High316.10 -1.19%Perf Year19.44%
Cash/sh1.73P/FCF21.95EPS past 3/5Y-9.17% -8.01%ROIC7.93%52W Low244.51 27.74%Perf 3Y45.52%
Dividend Est.2.88 (0.92%)EV/EBITDA14.89Sales past 3/5Y5.55% -0.04%Gross Margin27.85%Volatility3.78% 3.00%Perf 5Y28.41%
Dividend TTM2.88 (0.92%)EV/Sales2.23EPS Y/Y TTM36.76%Oper. Margin11.27%ATR (14)9.28Perf 10Y163.78%
Dividend Ex-DateAug 28, 2026Quick Ratio1.53Sales Y/Y TTM10.30%Profit Margin6.99%RSI (14)68.03Recom2.26
Dividend Gr. 3/5Y15.78% -Current Ratio1.80EPS Q/Q14.71%SMA207.35%Beta0.85Target Price319.33
Payout23.86%Debt/Eq0.83Sales Q/Q5.78%SMA5013.07%Rel Volume1.06Prev Close307.42
Employees71,000LT Debt/Eq0.75EarningsOct 27SMA20016.31%Avg Volume694.23KPrice312.34
IPO DateMar 29, 1990Option/ShortYes / YesEPS/Sales Surpr.4.41% 0.59%Net Debt/EBITDA3.08Volume735,167Change1.60%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-31-26ReiteratedDeutsche BankHold$276 → $306
Jul-31-26ReiteratedRobert W. Baird$338 → $352
Jul-31-26ReiteratedMorgan StanleyOverweight$303 → $338
May-01-26ReiteratedRobert W. Baird$332 → $334
Apr-08-26ReiteratedEvercore ISI GroupOutperform$305 → $300
Feb-24-26ReiteratedPiper SandlerNeutral$300
Feb-18-26ReiteratedRobert W. Baird$313 → $326
Jan-14-26ReiteratedRobert W. Baird$307 → $313
Oct-29-25ReiteratedRobert W. Baird$313 → $304
Oct-29-25ReiteratedUBSBuy$325 → $320
Latest News
Aug-04-26
Aug-04-2601:55PM
OPKO Health: Mazdutide And MDX-2201 Could Change EverythingSeekingAlpha
10:41AM
Here's Why Labcorp Holdings (LH) is a Strong Value Stockzacks.com
07:00AM
Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancerprnewswire.com
Jul-31-26
Jul-31-2608:04AM
Labcorp Q2 Earnings Call Highlightsmarketbeat.com
Jul-30-26
Jul-30-2602:43PM
Labcorp Holdings Inc. (LH) Q2 2026 Earnings Call Transcriptseekingalpha.com
12:31PM
LH Stock Down Despite Q2 Earnings and Revenue Beat, Margins Risezacks.com
10:31AM
Labcorp (LH) Reports Q2 Earnings: What Key Metrics Have to Sayzacks.com
09:06AM
Labcorp Holdings (LH) Surpasses Q2 Earnings and Revenue Estimateszacks.com
08:27AM
Labcorp raises annual profit forecast on strong testing demandreuters.com
06:50AM
Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidanceprnewswire.com
Jul-29-26
Jul-29-2610:16AM
Labcorp (LH) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimateszacks.com
Jul-27-26
Jul-27-2608:15PM
Top Stock Reports for Bank of America, Netflix & TotalEnergiesYahoo
08:00AM
Labcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testingprnewswire.com
Jul-24-26
Jul-24-2610:16AM
Labcorp Holdings Inc. (LH) Hit a 52 Week High, Can the Run Continue?zacks.com
08:26AM
Strength Seen in Labcorp (LH): Can Its 3.4% Jump Turn into More Strength?zacks.com
Company

Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue14,34913,95213,00912,16211,86413,13613,97911,55511,333
Cost of Goods Sold Incl. D&A10,35110,2199,3858,7978,1558,1449,0268,3028,157
Gross Profit3,9963,7333,6243,3653,7094,9924,9533,2533,176
Selling, General and Administrative Excl. Other2,2192,2162,2302,0211,9971,6901,7291,6251,571
Research and Development000200000
Other Operating Expense1600308616275254778243232
Operating Income1,6181,5161,0877261,4373,0492,4451,3301,326
Interest Expense227224208200180212207241244
Unusual Expense
—————————
Non-Operating Income (Expense)-156-1858143-1951-1915187
Net Income Before Taxes1,2341,1089605691,2372,8882,2191,1051,268
Income Taxes231230212189234690662280384
Consolidated Net Income1,0038777464181,2792,3771,556824884
Net Income From Continuing Operations1,0048787473801,0042,1981,557825884
Net Income1,0038777464181,2792,3771,556824884
EPS (Recurring)12.1710.548.894.8014.0424.5815.998.418.71
EPS (Basic, Before Extraordinaries)12.1710.548.894.8014.0424.5815.998.418.71
EPS (Diluted)12.0910.468.844.7713.9624.3815.888.368.61
EBITDA2,1522,0131,8111,3491,9543,6763,2522,1172,065
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio25.8323.9825.9447.6514.4911.0711.0117.3812.61
Price To Sales Ratio1.781.491.481.631.551.991.211.230.97
Gross Margin27.8526.7627.8627.6731.2638.0035.4328.1528.02
Operating Margin11.2810.878.365.9712.1123.2117.4911.5111.70
Net Margin6.996.295.733.4410.7818.1011.137.137.80
Shares Outstanding8283848791979798101
Market Capitalization25,61220,82319,26319,77418,40826,18316,96114,24210,964
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$326.48$302.75$279.03$255.31$231.58● Close Price0.00M0.77M1.55M2.32M3.10MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kyle Kathryn WEVP, Chief Legal OfficerJul 02 '26Sale286.199226,3293,904Jul 06
Vaughn Bryan TEVP and President, DiagnosticsJul 02 '26Sale286.1923466,9686,746Jul 06
Vaughn Bryan TEVP and President, DiagnosticsJul 01 '26Option Exercise0.0032707,073Jul 06
Kyle Kathryn WEVP, Chief Legal OfficerJul 01 '26Option Exercise0.0025604,069Jul 06
Kyle Kathryn WEVP, Chief Legal OfficerJun 08 '26Sale263.89762201,0843,813Jun 10
Schechter Adam HPresident & CEOMay 11 '26Sale254.505,9031,502,314107,234May 13
Meltzer Jonathan CEVP, OperationsMar 27 '26Sale267.05839224,0553,620Mar 30
Wilkinson Peter JSVP, Chief Accounting OfficerMar 27 '26Sale267.051,633436,0931,852Mar 30
Schechter Adam HPresident & CEOMar 03 '26Sale279.968,7052,437,04780,773Mar 05
van der Vaart Sandra DEVP, Corporate AffairsFeb 27 '26Sale284.91548156,0002,579Mar 03
Caveney Brian JEVP, Pres of ED, CMO & CSOFeb 24 '26Sale286.311,500429,45830,107Feb 26
Wilkinson Peter JSVP, Chief Accounting OfficerFeb 19 '26Sale277.94666185,1081,852Feb 23
Meltzer Jonathan CEVP, OperationsFeb 12 '26Sale290.428725,2672,782Feb 13
Wilkinson Peter JSVP, Chief Accounting OfficerFeb 11 '26Option Exercise0.0069602,564Feb 13
Wang Julia AijunChief Financial Officer, EVPFeb 11 '26Option Exercise0.0086002,062Feb 13
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.